Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Stress resistant human embryonic stem cells as a potential source for the identification of novel cancer stem cell markers.

Mousa SA, Sudha T, Dyskin E, Dier U, Gallati C, Hanko C, Chittur SV, Rebbaa A.

Cancer Lett. 2010 Mar 28;289(2):208-16. doi: 10.1016/j.canlet.2009.08.018. Epub 2009 Sep 4.

PMID:
19733430
2.

Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.

McCord AM, Jamal M, Shankavaram UT, Lang FF, Camphausen K, Tofilon PJ.

Mol Cancer Res. 2009 Apr;7(4):489-97. doi: 10.1158/1541-7786.MCR-08-0360. Erratum in: Mol Cancer Res. 2009 Jun;7(6):987. Shankavarum, Uma T [corrected to Shankavaram, Uma T].

3.

MicroRNA profiling of a CD133(+) spheroid-forming subpopulation of the OVCAR3 human ovarian cancer cell line.

Nam EJ, Lee M, Yim GW, Kim JH, Kim S, Kim SW, Kim YT.

BMC Med Genomics. 2012 May 29;5:18. doi: 10.1186/1755-8794-5-18.

4.

Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.

Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, Nuti M, Pierelli L, Testa U, Scambia G, Ferrandina G.

Clin Cancer Res. 2009 Jul 1;15(13):4299-311. doi: 10.1158/1078-0432.CCR-08-1883. Epub 2009 Jun 9.

5.

Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.

Botchkina IL, Rowehl RA, Rivadeneira DE, Karpeh MS Jr, Crawford H, Dufour A, Ju J, Wang Y, Leyfman Y, Botchkina GI.

Cancer Genomics Proteomics. 2009 Jan-Feb;6(1):19-29.

6.

A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy.

Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD.

Cancer Lett. 2010 Mar 28;289(2):151-60. doi: 10.1016/j.canlet.2009.08.010. Epub 2009 Sep 11.

PMID:
19748175
7.

Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line.

Vangipuram SD, Buck SA, Lyman WD.

Tumour Biol. 2012 Dec;33(6):2173-83. doi: 10.1007/s13277-012-0478-0. Epub 2012 Aug 11.

PMID:
22886526
8.

Active glycolytic metabolism in CD133(+) hepatocellular cancer stem cells: regulation by MIR-122.

Song K, Kwon H, Han C, Zhang J, Dash S, Lim K, Wu T.

Oncotarget. 2015 Dec 1;6(38):40822-35. doi: 10.18632/oncotarget.5812.

9.

Expression of multidrug resistance genes in normal and cancer stem cells.

Shervington A, Lu C.

Cancer Invest. 2008 Jun;26(5):535-42. doi: 10.1080/07357900801904140.

PMID:
18568776
10.

Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.

Guo R, Wu Q, Liu F, Wang Y.

Oncol Rep. 2011 Jan;25(1):141-6.

PMID:
21109969
11.

A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations.

Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, Price ND, Hood LE, Tian Q.

Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1591-6. doi: 10.1073/pnas.1018696108. Epub 2011 Jan 10.

12.

Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.

Tomuleasa C, Soritau O, Rus-Ciuca D, Pop T, Todea D, Mosteanu O, Pintea B, Foris V, Susman S, Kacsó G, Irimie A.

J Gastrointestin Liver Dis. 2010 Mar;19(1):61-7.

13.

Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?

Wei C, Guomin W, Yujun L, Ruizhe Q.

Cancer Biol Ther. 2007 May;6(5):763-8. Epub 2007 Feb 8.

PMID:
17592251
14.

Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.

Annabi B, Lachambre MP, Plouffe K, Sartelet H, Béliveau R.

Mol Carcinog. 2009 Oct;48(10):910-9. doi: 10.1002/mc.20541.

PMID:
19326372
15.

Limits of CD133 as a marker of glioma self-renewing cells.

Clément V, Dutoit V, Marino D, Dietrich PY, Radovanovic I.

Int J Cancer. 2009 Jul 1;125(1):244-8. doi: 10.1002/ijc.24352.

16.

Research progression of CD133 as a marker of cancer stem cells.

Zhang H, Li SY.

Chin J Cancer. 2010 Mar;29(3):243-7. Review.

17.

CD133 as a marker for cancer stem cells: progresses and concerns.

Wu Y, Wu PY.

Stem Cells Dev. 2009 Oct;18(8):1127-34. doi: 10.1089/scd.2008.0338. Review.

PMID:
19409053
18.

Overexpression of CD133 promotes drug resistance in C6 glioma cells.

Angelastro JM, Lamé MW.

Mol Cancer Res. 2010 Aug;8(8):1105-15. doi: 10.1158/1541-7786.MCR-09-0383. Epub 2010 Jul 27.

19.

Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?

Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ.

Biochem Biophys Res Commun. 2007 Apr 20;355(4):855-9. Epub 2007 Feb 6. Review.

PMID:
17307142
20.

Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, Roz E, Caserini R, Lo Vullo S, Camerini T, Mariani L, Delia D, Calabrò E, Pastorino U, Sozzi G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16281-6. doi: 10.1073/pnas.0905653106. Epub 2009 Sep 10.

Supplemental Content

Support Center